Further US progress for Tristel
Tristel plc in Newmarket has won a key registration for an infection control product in the US.
The United States Environmental Protection Agency (EPA) has registered the company’s foam-based chlorine dioxide product, Duo. The registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces.
The federal registration will be followed by state-by-state approvals which the company expects to complete by the end of 2018.
Tristel anticipates first revenues from the United States during its 2018-19 financial year.
CEO Paul Swinney said: “We have achieved our first United States regulatory approval and we will continue to pursue further registrations with the EPA and the Food and Drug Administration to build a broadly-based business in the USA.
“We recently announced that we have appointed Parker Laboratories Inc to manufacture Duo in its FDA approved facility in New Jersey and to sell Duo into the ultrasound marketplace in which they have national sales coverage. We will sell our products through different channels into other clinical areas in the US hospital market.
“This first United States approval is a very significant step for our company as it enables us to access the largest healthcare market in the world.
“It has been our long-held ambition to be recognised as a global brand in the infection prevention industry.
“An active presence in the United States is necessary to achieve this ambition and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal.”
• PHOTOGRAPH SHOWS: Tristel CEO, Paul Swinney